Advertisement

International Journal of Hematology

, Volume 75, Issue 5, pp 519–527 | Cite as

Flexible Low-Intensity Combination Chemotherapy for Elderly Patients with Acute Myeloid Leukemia

  • Arumugam Manoharan
  • Annette Trickett
  • Yiu Lam Kwan
  • Timothy Brighton
Case Report

Abstract

Twenty-five patients aged 57 to 88 years (median, 70 years) with acute myeloid leukemia were treated with a flexible low-intensity treatment regimen comprising mitozantrone (mitoxantrone) 6 mg/m2 administered by intravenous infusion ×3 days, cytarabine 10 mg/m2 subcutaneously every 12 hours ×7 to 14 days, and etoposide 100 mg orally ×7 to 14 days. Seventeen of these patients had a preexisting myelodysplastic syndrome. The clinical response was correlated to the results of cytogenetic studies (23 patients) and of viability studies of leukemic blasts (7 patients). Eleven of the 25 patients achieved complete remission (CR), 8 achieved partial remission (PR), and 4 showed no response. There was 1 toxic death, and 1 patient died soon (1 week) after presentation. Treatment was well tolerated. Although myelotoxicity occurred regularly, the recovery time was ≤3 weeks for most of the responding patients. Duration of survival for patients who had CR has ranged from 4+ to 43+ months and for patients who had PR, 3 to 16 months. Irrespective of the remission status (CR or PR), responding patients with favorable (n = 1) or intermediate (n = 10) cytogenetic findings had a significantly better survival time (median, 14 months) than did those with unfavorable (n = 7) cytogenetic findings (median, 5 months). In vitro studies showed a progressive reduction in the number of circulating blasts. The number of viable blasts 3 days after initiation of therapy appeared to give an early indication of clinical response. Treatment with a flexible low-intensity protocol seems to achieve results comparable with those reported for intensive antileukemia therapy and has much less toxicity.

Key words

Acute myeloid leukemia Elderly patients 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lancet JE, Wilman CL, Bennett JM.Acute myelogenous leukemia and aging: clinical interactions.Hematol Oncol Clin North Am.2000;14:251–267.CrossRefPubMedGoogle Scholar
  2. 2.
    Hamblin TJ. Disappointments in treating acute leukemia in the elderly.N Engl J Med. 1995;332:1712–1713.CrossRefPubMedGoogle Scholar
  3. 3.
    Manoharan A. Acute myeloblastic leukaemia in the elderly: biology, prognostic factors and treatment [review article].Int J Hematol. 1998;68:235–243.CrossRefPubMedGoogle Scholar
  4. 4.
    Feldman EJ, Seiter K, Damon L, et al. A randomized trial of high-vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia.Leukemia. 1997;11:485–489.CrossRefPubMedGoogle Scholar
  5. 5.
    Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy—the value of low-dose cytarabine for maintenance of remission and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report of the European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Co-operative Hovon Group.J Clin Oncol. 1998;16:872–881.CrossRefPubMedGoogle Scholar
  6. 6.
    Archimbaud E, Jehn U, Thomas X, et al. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.Leukemia. 1999;13:843–849.CrossRefPubMedGoogle Scholar
  7. 7.
    Manoharan A, Baker RI, Kyle PW. Low dose combination chemotherapy for acute myeloid leukemia in elderly patients: a novel approach.Am J Hematol. 1997;55:115–117.CrossRefPubMedGoogle Scholar
  8. 8.
    Slapak C, Desforges JF, Fogaren T, Miller KB. Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea and calcitriol.Am J Hematol. 1992;41:178–183.CrossRefPubMedGoogle Scholar
  9. 9.
    Yunis JJ, Lobell M, Arnesen MA, et al. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia.Br J Haematol. 1988;68:189–194.CrossRefPubMedGoogle Scholar
  10. 10.
    Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study.Blood. 1997;89:3323–3329.PubMedGoogle Scholar
  11. 11.
    Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of phos- phatidylserine expression on early apoptotic cells using fluorescein labelled annexin V.J Immunol Methods. 1995;184:39–51.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Hanon E, Lambot M, Hoornaert S, Lyaku J, Pastoret PP. Bovine herpesvirus I-induced apoptosis: phenotypic characterization of susceptible peripheral blood mononuclear cells.Arch Virol. 1998; 143:441–452.CrossRefPubMedGoogle Scholar
  13. 13.
    Lowenthal RM, Bradstock KF, Matthews JP, et al. A phase I/II study of intensive dose escalation of cytarabine in combination with idarubicin and etoposide in induction and consolidation treatment of adult acute myeloid leukemia. Australian Leukaemia Study Group (ALSG).Leuk Lymphoma. 1999;34:501–510.CrossRefPubMedGoogle Scholar
  14. 14.
    Steinmetz HT, Schulz A, Staib P, et al. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML.Ann Hematol. 1999;78:418–425.CrossRefPubMedGoogle Scholar
  15. 15.
    Anderson JE, Kopecky KJ, Head D, et al. A randomized phase III trial of mitoxantrone (M) + etoposide (E) versus daunomycin (CD) + cytarabine (A) as induction therapy in patients over age 55 with previously untreated acute myeloid leukemia (AML): Southwest Oncology Group Study 9333 [abstract].Blood. 1999;94(suppl 1):383a.Google Scholar
  16. 16.
    Baer MR, George SL, Dodge RK, et al. Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukemia (AML) patients (Pts) ≥60 years (CALGB 9720) [abstract].Blood. 1999;94(suppl 1):383a.Google Scholar
  17. 17.
    Shepherd JD, Nantel SH, Toze CL, et al. Therapy of acute myeloid leukemia in patients over 60 years of age with intermediate dose cytarabine, mitoxantrone and etoposide [abstract].Blood. 1999; 94(suppl 1):237b.Google Scholar
  18. 18.
    Frenette PS, Desforges JF, Schenkein DP, Rabson A, Slapak CA, Miller KB. Granulocyte-macrophage colony stimulating factor (GM-CSF) priming in the treatment of elderly patients with acute myelogenous leukemia.Am J Hematol. 1995;49:48–55.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kuriya SIU, Murai K, Miyairi Y, et al. A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage.Cancer. 1996; 78:422–426.CrossRefPubMedGoogle Scholar
  20. 20.
    Tsurumi H, Yamada T, Hara T, et al. Continuous infusion therapy with low dose cytosine arabinoside and etoposide in acute myelogenous leukemia patients hardly tolerable for intensive chemotherapy [abstract].Int J Hematol. 1996;64(suppl 1):5169.Google Scholar
  21. 21.
    Saito K, Nakamura Y, Aoyagi M, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML and refractory anemia with excess blasts in transformation.Int J Hematol. 2000;7l:238–244.Google Scholar
  22. 22.
    Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute non-lymphocytic leukemia in the elderly.J Clin Oncol. 1990;8:272–279.CrossRefPubMedGoogle Scholar
  23. 23.
    Fialkow PJ, Singer JW, Raskind WH, et al. Clonal development, stem-cell differentiation and clinical remissions in acute non-lymphocytic leukemia.N Engl J Med. 1987;317:468–473.CrossRefPubMedGoogle Scholar
  24. 24.
    Leyden M, Manoharan A, Boyd A, Cheng ZM, Sullivan J. Low-dose cytosine arabinoside: partial remission of acute myeloid leukaemia without evidence of differentiation induction.Br J Haematol. 1984; 57:301–307.CrossRefPubMedGoogle Scholar
  25. 25.
    Kojima H, Bai A, Hori T, Nagasawa T, Abe T. Role of apoptosis in cytotoxic chemotherapy for acute myelogenous leukemia [abstract].Blood. 1997;90(suppl 1):229b.Google Scholar
  26. 26.
    Bonelli G, Sacchi MC, Barbiero G, et al. Apoptosis of 929 cells by etoposide: a quantitative and kinetic approach.Exp Cell Res. 1996; 228:292–305.CrossRefPubMedGoogle Scholar
  27. 27.
    Sleiman RJ, Catchpoole DR, Stewart BW. Drug-induced death of leukaemic cells after G2/M arrest: higher order DNA fragmentation as an indicator of mechanism.Br J Cancer. 1998;77:40–50.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Hande KR. The importance of drug scheduling in cancer chemotherapy: etoposide as an example.Oncologist. 1996;1:234–239.PubMedGoogle Scholar
  29. 29.
    Manoharan A, Leyden MJ, Sullivan J. Low-dose cytarabine in acute myeloid leukaemia.Med J Aust. 1984;141:643–646.PubMedGoogle Scholar
  30. 30.
    Jackson GH, Taylor PRA, Iqbal A, et al. The use of an all oral chemotherapy (idarubicin and etoposide) in the treatment of acute myeloid leukaemia in the elderly: a report of toxicity and efficacy.Leukemia. 1997;11:1193–1196.CrossRefPubMedGoogle Scholar
  31. 31.
    Bouabdallah R, Lefrere F, Rose C, et al. A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients.Leukemia. 1999;13:1491–1496.CrossRefPubMedGoogle Scholar
  32. 32.
    Estey EH. How I treat older patients with AML.Blood. 2000;96: 1670–1673.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2002

Authors and Affiliations

  • Arumugam Manoharan
    • 1
  • Annette Trickett
    • 1
  • Yiu Lam Kwan
    • 1
  • Timothy Brighton
    • 1
  1. 1.Department of Clinical HaematologySt. George Hospital, University of New South WalesSydneyAustralia

Personalised recommendations